In a clinical trial in patients with residual HER2-negative invasive breast cancer evaluating adjuvant capecitabine following preoperative chemotherapy, the incidence of HFS in the capecitabine arm was as high as 73.4% [90]. The gene discussed is ERBB2; the disease is invasive breast carcinoma.